An announcement from Innovent Biologics ( (HK:1801) ) is now available.
Innovent Biologics, Inc. has announced a board meeting scheduled for March 26, 2025, to review and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend, which could impact shareholder returns and reflect the company’s financial health.
More about Innovent Biologics
Innovent Biologics, Inc. is a biotechnology company incorporated in the Cayman Islands, focusing on the development and commercialization of biologic therapies. The company is listed on the Hong Kong Stock Exchange and is involved in producing innovative treatments for various diseases.
YTD Price Performance: 9.28%
Average Trading Volume: 42,054
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $8.22B
See more insights into 1801 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com